ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Median PS Value : HK$0.00 (As of Dec. 14, 2024)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.001. ImmuneOnco Biopharmaceuticals (Shanghai)'s 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is HK$0.00.

As of today (2024-12-14), ImmuneOnco Biopharmaceuticals (Shanghai)'s share price is HK$6.02. ImmuneOnco Biopharmaceuticals (Shanghai)'s Median PS Value is HK$0.00. Therefore, ImmuneOnco Biopharmaceuticals (Shanghai)'s Price to Median PS Value for today is 0.00.

The historical rank and industry rank for ImmuneOnco Biopharmaceuticals (Shanghai)'s Median PS Value or its related term are showing as below:

HKSE:01541's Price-to-Median-PS-Value is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.7
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

ImmuneOnco Biopharmaceuticals (Shanghai) Median PS Value Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Median PS Value Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Median PS Value

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Median PS Value	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Median PS Value

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Median-PS-Value falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Median PS Value Calculation

ImmuneOnco Biopharmaceuticals (Shanghai)'s Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	0.001	*	0
	=	0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.001.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	6.02	/	0.00
	=

ImmuneOnco Biopharmaceuticals (Shanghai) Median PS Value Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Median PS Value

Comparable Companies

Traded in Other Exchanges

R9Z:Germany

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines